DNase I and other NETs‐disrupting approaches have been explored in preclinical and clinical settings for inflammatory and thrombotic diseases, raising the possibility of repurposing NETs‐targeting agents to modulate the immunosuppressive microenvironment in PDAC. This evidence concerns the gene DNASE1 and thrombotic disease.